GSK seeks approval for diabetes drug albiglutide

01/14/2013 | Reuters

GlaxoSmithKline has filed for FDA approval for albiglutide, its once-weekly diabetes drug. Albiglutide is an injectable GLP-1 drug and belongs to the same class as Novo Nordisk's Victoza and Bristol-Myers Squibb and AstraZeneca's Byetta and Bydureon.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC